Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.

Objectives: The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate.

Methods: We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30.

Generating-sensation and propagating-myoelectrical responses along the meridian.

The meridian phenomena are closely associated with the neuro-muscular function. Our experiments show that meridian phenomenon, acupoint stimulation-induced generating-sensations along meridians (GSM), does exist in some volunteers, and the subjects can describe the characteristics of the feelings and the route of GSM. Simultaneously, GSM is often accompanied with progressive myoelectric activity along the meridian which is able to be recorded objectively.